Amphotericin B is indicated for:
Population group: both men and women, only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Amphotericin B is indicated in adults and children aged 1 month to 18 years old for the treatment of severe systemic and/or deep mycoses.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Amphotericin B is indicated for the treatment of visceral leishmaniasis in immunocompetent patients including both adults and children.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Amphotericin B is indicated in adults and children aged 1 month to 18 years old for the empirical treatment of presumed fungal infections in febrile neutropenic patients, where the fever has failed to respond to broad spectrum antibiotics and appropriate investigations have failed to define a bacterial or viral cause.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Amphotericin B is contraindicated in the following cases: